Bridge Therapeutics Inc.

📍 Birmingham, United States🗓 Founded 2016👥 4 employees💰 Last funded Nov 2021
Pharmaceutical Manufacturing🌐 bridgetherapeutics.com
Website LinkedIn
Bridge Therapeutics®, based in Birmingham, Ala., is an innovative development-stage specialty pharmaceutical company pursuing U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals of a patented (U.S. Patent #8410092) drug combination, BT-205, for the treatment of chronic pain in opioid-experienced patients. The investigational drug BT-205 is a unique combination of two synergistic chronic pain drugs—the partial-agonist opioid buprenorphine and the NSAID meloxicam—delivered in a state-of-the-art sublingual formulation. The dosing and delivery method will be a commercial advantage over the current alternatives. Bridge Therapeutics​ goal is to make the BT-205 compound and other investigational new drug candidates available to millions of patients in which addictive and potentially dangerous full-agonist opioids such as oxycodone and morphine are ineffective and/or unsatisfactory. For more information, visit www.bridgetherapeutics.com.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2016
Founded

Investors

1 investor
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Bridge Therapeutics Inc.?
Bridge Therapeutics Inc. has 1 investor on record on gritt.io, 1 mid-stage.
When did Bridge Therapeutics Inc. last raise funding?
The most recent investment in Bridge Therapeutics Inc. recorded on gritt.io was in November 2021.
When was Bridge Therapeutics Inc. founded?
Bridge Therapeutics Inc. was founded in 2016.
What industry is Bridge Therapeutics Inc. in?
Bridge Therapeutics Inc. operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Bridge Therapeutics Inc. based?
Bridge Therapeutics Inc. is headquartered in Birmingham, United States.